The Pharma Data

DECEMBER 30, 2020

This week, Bloomberg reported companies agreed to slash the prices of 119 new therapies that treat a range of illnesses, including pulmonary disease, lupus, diabetes and cancer. Belarus was also the first foreign country to begin clinical trials of Sputnik V. Relief Therapeutics – Switzerland-based Relief Therapeutics and U.S.-based

Immune Response 52

Immune Response Vaccine Clinical Trials Production 52

Drug Target Review

APRIL 3, 2024

Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences. Everything started in school with an experiment on isolating DNA from bananas. in North America) in late 2017.

Science 105

Science Clinical Development DNA Treatment 105

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Clinical Trials 130

Clinical Trials Research Science Clinical Research 130

The Pharma Data

NOVEMBER 19, 2020

Centers for Disease Control and Prevention (CDC), there were more than 216,000 confirmed COVID-19 cases in healthcare workers in the U.S., The results were published in the journal BMC Infectious Diseases. “We Deep Sleep May Protect Against Alzheimer’s Disease. As of November 15, 2020, according to the U.S. Working with C.

Research 52

Research Nurses Disease Immune Response 52

The Pharma Data

JULY 6, 2021

“Breaking barriers for people living with rare blood disorders requires that we push ourselves to transform the therapeutic landscape, ” said Karin Knobe, MD, PhD, Head of Development, Rare Disease s and Rare Blood Disorders at Sanofi. “We Three additional Phase 2 studies in immunological diseases are planned to start in 2021.

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

Drug Discovery World

JULY 22, 2022

Immunotherapies have become more popular due to their ability to trigger and train the patient’s immune system to recognise and attack tumour cells, provide strong immune responses, and reduce the severity of adverse side effects generally associated with chemotherapies. Exp Mol Ther.Published online 2018:LB-088-LB-088.doi:10.1158/1538-7445.am2018-lb-088.

Therapies 130

Therapies Treatment Engineering Clinical Trials 130

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 27, 2020

This year has been difficult, but it has reinforced the importance of our mission: to treat and potentially even reverse the effects of serious diseases and conditions by advancing our novel cell therapy product candidates through clinical trials and into the hands of physicians.

Therapies 52

Therapies Production Clinical Trials Treatment 52

Drug Discovery World

FEBRUARY 6, 2023

It’s a rapid growth area for clinical trials in the next few years as we seek to understand the underlying biology behind many of the targets and diseases we study. Results provide deep insights into mechanistic processes, such as which innate and adaptive immune system processes are activated following vaccination and when.

Bioinformatics 130

Bioinformatics RNA Vaccine Clinical Trials 130

Codon

JULY 14, 2024

However, the subsequent death of another patient thrust Denys into a contentious trial. In contrast, people with sickle cell disease commonly receive red blood cell transfusions to alleviate vaso-occlusive pain crises. The results of the trial are expected at the end of 2024. In the U.S., million units transfused.

Production 133

Production Clinical Trials Trials Therapies 133

The Pharma Data

SEPTEMBER 2, 2021

RSV is a significant cause of severe respiratory disease in older adults, and it can cause disability and death. There is an important unmet medical need for an effective vaccine that can help protect older adults against this highly-contagious disease,” said Kathrin U. Jansen, Ph.D., 2 In the U.S., Source link: [link].

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

The Pharma Data

NOVEMBER 9, 2020

Trial Also Met the Primary Endpoint in Patients With Low Levels of Eosinophils. In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter, the trial met the primary endpoint with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

DECEMBER 21, 2020

21, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticosteroid (OCS) dose, without loss of asthma control, with tezepelumab compared to placebo. THOUSAND OAKS, Calif. ,

Trials 40

Trials Production Clinical Trials Government 40

Drug Target Review

FEBRUARY 28, 2024

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. Human γδ TCR repertoires in health and disease. Trends Immunol 39(6):446-459 (2018).

Therapies 105

Therapies Engineering Molecular Biology Immune Response 105

The Pharma Data

JULY 8, 2021

“Severe asthma is a challenging, complex disease for physicians and millions of patients and has a high unmet medical need,” said David M. 8) There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial.(8) Reese, M.D., About Severe Asthma.

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

JUNE 18, 2021

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Following today’s FDA approval, the U.S. Jansen, Ph.D.,

Vaccine 52

Vaccine FDA Approval FDA Disease 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. For instance, a single nucleotide substitution in HSD17B13 has a protective effect against NASH and fatty liver disease (FLD).

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

MARCH 3, 2022

Pfizer will publish outcomes from this clinical trial at a future date. Today’s decision is a pivotal next step in our path towards potential regulatory approval for our maternal RSV vaccine candidate and is an important milestone in our efforts to help address the detrimental impact RSV disease has on infants,” said Kathrin U.

Virus 52

Virus Vaccine Clinical Trials FDA 52

The Pharma Data

AUGUST 22, 2021

The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442. The trial included 5,197 participants in a 2:1 randomisation AZD7442 to placebo. The trial was conducted in 87 sites in the US, UK, Spain, France and Belgium.

Trials 52

Trials Virus Vaccine Pharmacokinetics 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was 375,400, with 167,142 deaths caused by cancer between 2017 and 2019. This continues to be the standard of care.

Research 130

Research Therapies Immune Response Clinical Trials 130

The Pharma Data

SEPTEMBER 5, 2021

“This new analysis from NAVIGATOR is exciting for the up to one in five severe asthma patients who have comorbid nasal polyps,” said Professor Andrew Menzies-Gow, director of the Lung Division, Royal Brompton Hospital, London, UK, the principal investigator of the NAVIGATOR trial.

Trials 52

Trials Clinical Trials Therapies Treatment 52

The Pharma Data

OCTOBER 26, 2020

The purpose of this exploratory Phase 1b/2 trial was to evaluate the safety and efficacy of the combination of TG4001 and an immune checkpoint inhibitor in a heterogeneous group of patients with aggressive, recurrent and/or metastatic HPV16-positive cancers. Key findings of the trial: .

Vaccine 52

Vaccine Virus Trials Treatment 52

The Pharma Data

OCTOBER 28, 2020

29, 2020 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the potential pathway to marketing approval for its lead product candidate remestemcel-L. The dosing regimen in the Phase 3 is the same as in the pilot trial.

Treatment 40

Treatment Trials Production Disease 40

The Pharma Data

JUNE 30, 2021

Approval based on Phase 2 CheckMate -142 trial results showing nearly two-thirds of patients responded to the Opdivo plus Yervoy combination with durable responses observed. Results from the CheckMate -142 trial at minimum follow-up of 46.9 achieving a complete response. Waxman, M.D.,

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 2018) PLoS One.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

FEBRUARY 8, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0% In 2020, Rare Disease sales increased 5.7% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks. Rare Disease. Others Rare Disease. Total Rare Disease. In the fourth quarter, Rare Disease sales increased 3.0% In 2020, Rare Disease sales increased 5.7% Net sales (€ million).

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

APRIL 27, 2021

reflecting increased competition partially offset by demand growth partly related to clinical trial supply and price upside in Europe. to €24 million, primarily due to the COVID-19 pandemic, which has led to a decrease in infused immune reconstitution therapies such as Lemtrada ®. Rare Disease. Others Rare Disease.

Vaccine 52

Vaccine Production FDA FDA Approval 52

Drug Discovery World

SEPTEMBER 29, 2022

Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need. . Allison August, M.D., The potential future of mRNA in CMV prevention . References. Whitley RJ. Herpesviruses.

Vaccine 130

Vaccine Immune Response Virus Disease 130

The Pharma Data

MAY 13, 2021

Health authorities in Guinea officially declared a new Ebola outbreak in February 2021 after the West African country experienced its first cases of disease since the end of the 2014-2016 Ebola outbreak – which was the worst on record. Global Head, Global Public Health Research & Development, Johnson & Johnson. “We

Vaccine 52

Vaccine Virus Pharmaceutical Companies Clinical Trials 52